TRIM21 and cutaneous vasculitis: Patients with cutaneous vasculitis had a higher prevalence of ANA positivity (75% vs. 70.4%, p = 0.012), RF (65% vs. 22.5%, p < 0.0001), anti-Ro/SS-A antibodies (70% vs. 62.3%, p = 0.014), anti-La/SS-B antibodies (55% vs. 16%, p < 0.0001) compared with pSS patients without vasculitis.